Anti-infective vaccination strategies in patients with haematological malignancies or solid tumours: updated guideline of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology.
3/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: cancer starting from 2017, as this was the data cutoff for the previous guideline, and for newly included vaccines all publications were reviewed
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Guidance has been added for patients receiving novel therapies such as tyrosine kinase inhibitors, bispecific antibodies, and chimeric antigen receptor T cells. This guideline addresses the urgent medical need to reduce vaccine-preventable diseases and aims to improve vaccination uptake among patients with cancer and their caregivers.
OpenAlex 토픽 ·
Neutropenia and Cancer Infections
Lymphadenopathy Diagnosis and Analysis
Immunotherapy and Immune Responses
Vaccine-preventable infections remain a major cause of morbidity and mortality in patients with cancer.
APA
Sibylle C. Mellinghoff, Blasius Liss, et al. (2026). Anti-infective vaccination strategies in patients with haematological malignancies or solid tumours: updated guideline of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology.. The Lancet. Oncology, 27(4), e195-e206. https://doi.org/10.1016/S1470-2045(25)00765-X
MLA
Sibylle C. Mellinghoff, et al.. "Anti-infective vaccination strategies in patients with haematological malignancies or solid tumours: updated guideline of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology.." The Lancet. Oncology, vol. 27, no. 4, 2026, pp. e195-e206.
PMID
41926972 ↗
Abstract 한글 요약
Vaccine-preventable infections remain a major cause of morbidity and mortality in patients with cancer. The updated guideline for anti-infective vaccination strategies in patients with cancer of the German Society of Hematology and Medical Oncology Infectious Diseases Working Group was developed by a guideline panel of experts in internal medicine, haematology, medical oncology, and infectious diseases. For previously covered vaccinations, we included all publications in patients with cancer starting from 2017, as this was the data cutoff for the previous guideline, and for newly included vaccines all publications were reviewed. After data extraction and critical discussion, the recommendations were graded following a standardised international grading system. This update introduces general recommendations, optimal vaccination timing, potential use of live vaccines, and immunisation of close contacts and household members of patients. Moreover, specific sections for patients with solid tumours and patients with haematological malignancies have been introduced. Guidance has been added for patients receiving novel therapies such as tyrosine kinase inhibitors, bispecific antibodies, and chimeric antigen receptor T cells. This guideline addresses the urgent medical need to reduce vaccine-preventable diseases and aims to improve vaccination uptake among patients with cancer and their caregivers.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.